



MEMORANDUM

Date: June 13 2023

From: Varsha Garnepudi M.S.
Quality Assurance Branch (QAB)
Division of Biological Standards and Quality Control (DBSQC)
Office of Compliance and Biologics Quality (OCBQ)
Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)

To: Biologics License Application Submission Tracking Numbers 125781/0

Subject: Review of Lot Release Protocol (LRP) Template for delandistrogene
moxeparvovec- rokl for the treatment of ambulatory patients with Duchenne
muscular dystrophy (DMD) with a confirmed mutation in the *DMD* gene
using an adeno-associated virus (AAV) vector-based gene therapy

Through: Maryna Eichelberger, Ph.D., Director, DBSQC/OCBQ/CBER/FDA

Cc: Emmanuel Adu- Gyamfi, PhD, Chair, GTB1/DGT1/OGT/OTP/CBER/FDA
Rachel Duddy, RPM, RMSB2/DRMRR2/ORMRR/OTP/CBER/FDA

Applicant: Sarepta.

Products: delandistrogene moxeparvovec-rokl
Trade Name – ELEVIDYS

1 General Information

1.1 CMC Review Identifiers and Dates

1.1.1 Biologics License Application (BLA) Submission Tracking Number (STN):
125781/0

1.1.2 Submission received by CBER: September 22, 2022

1.1.3 Review completed: June 06, 2023

1.1.4 Material Reviewed: BLA 125781

1.1.5 Related Master File, INDs and BLAs:

2 Review

2.1 Documents Reviewed

LRP template for delandistrogene moxeparvovec - rokl submitted in BLA 125781/0 on September 22, 2022.

LRP template for delandistrogene moxeparvovec - rokl submitted in BLA 125781/0.12 on January 11, 2023.

LRP template for delandistrogene moxeparvovec - rokl submitted in BLA 125781/0.45 on April 26, 2023.

LRP template for delandistrogene moxeparvovec – rokl submitted in BLA 125781/0.52 on May 10, 2023.

LRP template for delandistrogene moxeparvovec - rokl submitted in BLA 125781/0.66 on June 07, 2023.

2.2 Review

On September 22, 2022, Sarepta Therapeutics Inc. submitted BLA 125781/0 for delandistrogene moxeparvovec-rokl. The submission was missing the lot release protocol template. An IR was sent to Sarepta on January 06, 2023, asking them to submit a LRP template that includes the release specifications for the drug substance and drug product along with the test parameter, method type, and acceptance criteria.

A response and revised LRP template were submitted in amendment 125781/0.12 on January 11, 2023. This template was reviewed by OGT/DGT1/GTB1, OCBQ/DMPQ/PRB, and OCBQ/DBSQC with comments from GTB1, PRB and DBSQC.

An IR was sent to Sarepta on April 19, 2023, to submit a revised LRP template to include several formatting changes and remove the pages 1- 4 from DS, DP template and to combine the data for DS and DP in ONE LRP template. In addition, information was provided regarding launch lots and the mechanism to submit LRPs. Templates were provided for Sterility, (b) (4) assay, Bioburden, eLRP signature letter, Electronic Protocol page 1 and sample submission form.

A response and revised LRP template were submitted in amendment 125781/0.45 on April 26, 2023. This template was reviewed by OGT/DGT1/GTB1, OCBQ/DMPQ/PRB, and OCBQ/DBSQC with comments from PRB and DBSQC.

An IR was sent to Sarepta on May 08, 2023, to submit a revised LRP template to remove page 1 from the front of the protocol and to include (b) (4) rows, one for (b) (4) of each run of the Endotoxin assay and to include (b) (4) rows one for each media type for the Sterility assay. Templates were provided for the Sterility and Endotoxin assay.

The updated template was submitted in amendment 125781/0.52 on May 10, 2023. This template was reviewed by OCBQ/DMPQ/PRB and OCBQ/DBSQC OGT/DGT1/GTB1 with additional comments.

An IR was sent to Sarepta on June 02, 2023, by product office CMC reviewer, to submit a revised LRP template to include updated specifications for a few tests and to add a foot note for the endotoxin assay.

The updated template was submitted in amendment 125781/0.66 on June 07, 2023. This template was reviewed by OCBQ/DBSQC OGT/DGT1/GTB1 with no additional comments

Conclusions

The LRP template for delandistrogene moxeparvovec- rokl submitted in amendment 125781/0.66 on June 07, 2023, is acceptable for use. This template may be used for future lot release submissions. To prepare to review LRPs submitted to CBER, a testing plan and LRP routing slip are being developed.